Skip to main content

Strides Pharma acquires FDA OK for generic butalbital, acetaminophen and caffeine


Patients seeking relief of the symptom complex of tension (or muscle contraction) headache will soon have a new generic treatment.

Strides Pharma has received the Food and Drug Administration’s blessing for butalbital, acetaminophen, and caffeine tablets in a dosage strength of 50 mg/325 mg/40 mg.

The product is the generic of Actavis Laboratories’ butalbital, acetaminophen, and caffeine tablets.

It had a market value of roughly $40 million, according to IQVIA July 2020 data.

This ad will auto-close in 10 seconds